Skip to main content
OpenTrials

Clinical trial condition

Relapsed or Refractory Multiple Myeloma

Explore clinical trials studying Relapsed or Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

44 public trials 13 recruiting studies
Refine in advanced search Browse all conditions

Relapsed or Refractory Multiple Myeloma trial results

Completed

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

NCT06163040

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Chang Gung Memorial Hospital- Chiayi Chiayi City, Chiayi, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • National Taiwan University Hospital Taipei, Taiwan
  • China Medical University Hospital Taoyuan City, Taiwan
View Trial Details
Completed

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

NCT06055075

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Alexandra Hospital Woolloongabba Woolloongabba, Queensland, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Hamilton Health Sciences Hamilton, Ontario, Canada
  • Istituto Clinico Humanitas Rozzano, Lombardy, Italy
View Trial Details
Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • James R. Berenson, MD, Inc. West Hollywood, California, United States
  • Northside Hospital Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinical Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

NCT02939183

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Research Site West Hollywood, California, United States
  • Research Site Tampa, Florida, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03859427

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Bone Marrow Neoplasms, +21 more
Locations
  • Robert A Moss Oncology Fountain Valley, California, United States
  • Rocky Mountain Cancer Centers Denver Midtown Denver, Colorado, United States
  • Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut Plainville, Connecticut, United States
  • Baptist MD Anderson Cancer Center Jacksonville, Florida, United States
View all 108 locations
View Trial Details
Completed

Selinexor, Cyclophosphamide and Prednisone in Myeloma

NCT06212596

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Birmingham Heartlands Hospital Birmingham, United Kingdom
  • Royal Bournemouth Hospital Bournemouth, United Kingdom
  • Leicester Royal Infirmary Leicester, United Kingdom
  • Royal Liverpool University Hospital Liverpool, United Kingdom
View all 13 locations
View Trial Details
Completed

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

NCT02834364

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
Locations
  • Universitätsklinikum Köln, Klinik I Innere Medizin Cologne, Germany
  • Mediz. Klinik und Poliklinik 1, Universitätsklinikum Dresden Dresden, Germany
  • Universitätsklinikum Frankfurt, Medizinische Klinik II Frankfurt am Main, Germany
  • University Hospital Heidelberg, Med. Klinik V Heidelberg, Germany
View Trial Details

Related conditions